Ether

Ether

SCHEMBL954914

CCOCC.O=C(O)COCc1ccccc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
TSHR P16473 1/20 0.50
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
GLA P06280 1/20 0.49
NPC1 O15118 2/20 0.47
MAPT P10636 1/20 0.47
PAM P19021 1/20 0.46
GRM5 P41594 1/20 0.45
CSNK1D P48730 1/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231282 0.90 TSHR (0.61) ALDH1A1TSHRRAB9AL3MBTL1NPC1
Hydrochloric Acid SCHEMBL7053203 0.88 TSHR (0.58) ALDH1A1TSHRRAB9AL3MBTL1NPC1
SCHEMBL4226282 0.88 TSHR (0.58) ALDH1A1TSHRRAB9AL3MBTL1NPC1
Acetic Acid SCHEMBL28567289 0.87 ALDH1A1 (0.55) ALDH1A1TSHRRAB9ASMN1; SMN2L3MBTL1
SCHEMBL21657315 0.86 FFAR4 (0.44) ALDH1A1RAB9ASMN1; SMN2L3MBTL1GLA
SCHEMBL29928468 0.86 FFAR4 (0.44) ALDH1A1RAB9ASMN1; SMN2L3MBTL1GLA
Ethylbenzene SCHEMBL27718341 0.83 ALDH1A1 (0.56) ALDH1A1TSHRRAB9ASMN1; SMN2L3MBTL1
Ether SCHEMBL10609432 0.82 TSHR (0.75) ALDH1A1TSHRRAB9ASMN1; SMN2L3MBTL1
Ether SCHEMBL19744986 0.82 TSHR (0.75) ALDH1A1TSHRRAB9ASMN1; SMN2L3MBTL1
SCHEMBL1956559 0.81 TSHR (0.54) ALDH1A1TSHRSMN1; SMN2L3MBTL1PAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009429-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 NOVARTIS AG (CH) 2011-01-13 US disclosed
EP-2257552-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 Novartis AG (CH) 2010-12-08 EP disclosed
WO-2009106539-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 NOVARTIS AG (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009429-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 CXCR2, CXCR1, CXCR3 ALDH1A1 1082/4885TSHR 1428/4885RAB9A 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.